Evidence map›Paper›PMID 26156138›Full record

SynthesisScientific reports2015

Plasmakinetic resection technology for the treatment of benign prostatic hyperplasia: evidence from a systematic review and meta-analysis.

Sheng Li, Joey S W Kwong, Xian-Tao Zeng, Xiao-Lan Ruan, Tong-Zu Liu, Hong Weng, Yi Guo, Chang Xu, Jin-Zhu Yan, Xiang-Yu Meng and 1 more

Open access · goldAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 3 pooled it
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 3 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Sheng Li1] Department of Urology, Zhongnan Hospital, Wuhan University, Wuhan, People's Republic of China [2] Center for Evidence-based and Translational Medicine, Wuhan University, Wuhan, People's Republic of China.
Joey S W KwongChinese Evidence-Based Center and Chinese Cochrane Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, People's Republic of China.
Xian-Tao Zeng1] Department of Urology, Zhongnan Hospital, Wuhan University, Wuhan, People's Republic of China [2] Center for Evidence-based and Translational Medicine, Wuhan University, Wuhan, People's Republic of China.
Xiao-Lan RuanDepartment of Hematology, Renmin Hospital of Wuhan University, Wuhan, People's Republic of China.
Tong-Zu LiuDepartment of Urology, Zhongnan Hospital, Wuhan University, Wuhan, People's Republic of China.
Hong WengCenter for Evidence-based and Translational Medicine, Wuhan University, Wuhan, People's Republic of China.
Yi GuoDepartment of Epidemiology, School of Public Health, Wuhan University, Wuhan, People's Republic of China.
Chang XuDepartment of Urology, Zhongnan Hospital, Wuhan University, Wuhan, People's Republic of China.
Jin-Zhu YanCenter for Evidence-based and Translational Medicine, Wuhan University, Wuhan, People's Republic of China.
Xiang-Yu MengCenter for Evidence-based and Translational Medicine, Wuhan University, Wuhan, People's Republic of China.
Xing-Huan Wang1] Department of Urology, Zhongnan Hospital, Wuhan University, Wuhan, People's Republic of China [2] Center for Evidence-based and Translational Medicine, Wuhan University, Wuhan, People's Republic of China.
Wuhan University · CNZhongnan Hospital of Wuhan University · CNRenmin Hospital of Wuhan University · CNSichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to compare plasmakinetic resection of the prostate (PKRP) with transurethral resection of the prostate (TURP) for benign prostatic hyperplasia (BPH) in terms of efficacy and safety. Published RCTs were searched from PubMed, Embase, Science Citation Index, and Cochrane Library up to April 10, 2014. After methodological quality assessment and data extraction, meta-analysis was performed using the STATA 12.0 software. 18 reports of 16 RCTs were included in this analysis. Meta-analyses showed that PKRP significantly improved Qmax at 12 months, but no significant difference was found for other efficacy outcomes. In terms of safety, treatment of PKRP was associated with reduced drop in serum sodium, lower TUR syndrome, reduced need of blood transfusion, clot retention, and shorter catheterization time and hospital stay; in contrast, there were no significant differences in the analysis of operative time, postoperative fever, and long-term postoperative complications. In summary, current evidence suggests that, although PKRP and TURP are both effective for BPH, PKRP is associated with additional potential benefits in efficacy and more favorable safety profile. It may be possible that PKRP may replace the TURP in the future and become a new standard surgical procedure.

Indexed as

Follow-Up StudiesHumansMalePostoperative ComplicationsProstatectomyProstatic HyperplasiaPublication BiasQuality of LifeTransurethral Resection of ProstateTreatment Outcome

Identifiers

PMID26156138
PMCPMC4496666
OpenAlexW2252791495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.